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This month's journal reports two studies using the combination of
irinotecan and cisplatin in advanced non-small-cell lung cancer.
The first is a phase II study that achieves a high response rate of
54%, with 33% of patients alive at 1 year (Masuda et al, 1998).
The second is a phase I dose-finding study of the same combina-
tion but given with concomitant radiotherapy in locally advanced
disease. The initial doses chosen were of the order of 40% of the
usual irinotecan weekly dose with 60 mg m-2 cisplatin. This
chemoradiotherapy combination was not tolerated because of a
number of toxicities, but in particular leucopenia. The study was
stopped early but even at these low doses, a response rate of 67%
was obtained (Yokoyama et al, 1998). This has important implica-
tions for the use of irinotecan with radiotherapy in both lung and
bowel cancer (Yokoyama et al, 1998).
Where do we take these new treatments and how do we make
progress in the treatment of non-small-cell lung cancer? We now
have five new drugs with activity in non-small-cell lung cancer
and all of them priced in the range of between 6 and 30 times the
cost ofany ofour previous regimens. This compounds the problem
in non-small-cell lung cancer when the last new drug in the late
1980s, vinorelbine, has yet to be tested or accepted as standard
treatment in this country. Currently, drug budgets are stretched to
meet the increasing expenditure with our current 'cheap' regi-
mens, never mind addressing new expensive treatments. It is a
shame that we have come to the point when new treatments are not
being hailed into clinical trials with enthusiasm and optimism, as
currently there are no prospects that these new agents, ifbetter, can
then become standard treatments.
Gemcitabine, the taxanes (paclitaxel, docetaxel), the topoiso-
merase I inhibitors (irinotecan, topotecan) and vinorelbine all have
significant single-agent activity with response rates ofat least 20%
and encouraging survival data with acceptable toxicities (Table 1).
There have now been numerous phase II studies investigating
these agents in combination with platinum compounds, including
the two in this issue. They have shown promising activity with
relatively high response rates and 1-year survivals of40% or more
(Table 2). However, although promising, these phase II studies
must be viewed with caution, andjudgment must be reserved until
the results of phase III randomized studies comparing these
combinations to standard treatments become available.
The commonest (standard) treatments for non-small-cell lung
cancer in this country are cisplatin based, usually MVP (mitomycin,
vinblastine and cisplatin) or MIC (mitomycin, ifosfamide and
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cisplatin), with cisplatin used at a dose of around 50 mg m-2. This
differs to the USA where the cisplatin dose is usually higher and the
combinations most frequently used are etoposide/cisplatin and
vinblastine/cisplatin. The only randomized study comparing MIC,
MVP (both using higher-dose cisplatin) and etoposide/cisplatin
resulted in significant response and survival advantage for both
three-drug regimens (Crino et al, 1995). The use ofhigher cisplatin
doses was based on one small randomized trial that demonstrated
longer duration ofresponse and a survival advantage forresponders
in the higher dose arm, but no overall survival results were reported
(Gralla et al, 1981). However, three subsequent larger randomized
studies have failed to show advantage for the higher cisplatin doses,
and toxicity was considerably worse (Klastersky et al, 1986;
Gandara, 1993; Felip et al, 1997).
The first randomized study using new agents compared vinorel-
bine/cisplatin to vindesine/cisplatin to vinorelbine alone in 612
patients. The vinorelbine/cisplatin combination resulted in a
significantly superior response rate (30% vs 19% vs 14%),
survival (median survival in weeks 40 vs 32 vs 31) and 1-year
survival (35% vs 27% vs 30%) (Le Chevalier et al, 1996). This
study changed practice in the USA where vinorelbine/cisplatin is
now standard therapy. Two more recent randomized studies
comparing vinorelbine/cisplatin with either cisplatin alone or
vinorelbine alone have further established the superiority of this
combination (Gil Deza et al, 1996; Wozniak et al, 1996).
The first of the studies using paclitaxel (Taxol) in combination
with Cisplatin are now appearing. The ECOG study compared two
doses of paclitaxel (250 and 135 mg m-2) with cisplatin to etopo-
side/cisplatin (Bonomi et al, 1997). Both paclitaxel/cisplatin doses
resulted in similar response rates that were higher than the etopo-
side/cisplatin arm (27.7% vs 25.3% vs 12.4%). Hence, the two
paclitaxel/cisplatin arms were combined for the survival analysis.
The median survival was extended by about 2 months (9.8 vs 7.7
months, P = 0.048) in the paclitaxel/cisplatin arms, with an
improvement in the 1-year survival (38.5% vs 31.6%). The EORTC
have carried out a similar study, again comparing cisplatin and
paclitaxel (175 mg m-2) against their standard regimen ofcisplatin
and teniposide. Again, the response rate for the pacilitaxel combi-
nation was higher (44% vs 30%), but median survival was similar
in both arms (9.4 vs 9.7 months) (Giaccone et al, 1997).
The third new agent to reach preliminary analysis in random-
ized trials is gemcitabine. A recently reported Taiwanese trial
compared gemcitabine alone to etoposide/cisplatin. The response
rate and survival were similar in both arms but the toxicity profile
and inpatient days were markedly better in the gemcitabine arm
(Perng et al, 1997). This indicates that gemcitabine is a very well
tolerated agent that would be suitable for palliative treatment of
even elderly and frail patients. Finally, a Spanish study has
compared gemcitabine/cisplatin to etoposide/cisplatin. This study
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Table 1 New drug single-agent activity in untreated patients with non-small-cell lung cancer
Number Response rates (%) Median survival (weeks) References
Gemcitabine 438 (5)a 21 (95% Cl 16-25) 26-46 (Hansen,1997)
Vinorelbine 1146 (15) 23.6 ± 9.6 32.5 + 4.1 (Le-Chevalier, 1997)
Paclitaxel 316 (10) 27 (Range 10-56) 37 (24-56) (Bunn,1997)
Docetaxel 160 (4) 30 (95% Cl 21-35) 39 (Fossella, 1997)
Irinotecan 72 (1) 31.9 (95% Cl 20-44) 42 (Fukuoka et al, 1992)
Topotecan 78 (2) 15-18.4 36-38 (Fukuoka,1997)
aNumber of trials in parentheses.
Table 2 New drug combination regimens in untreated patients with non-small-cell lung cancer
Number Response rate (%) Median survival 1-Year survival (%) References
Gemcitabine-cisplatin 284 (7)a 46 (Range 30-54) 7.6-15.4 months 33-59 (Crino, 1997)
Vinorelbine-cisplatin 1024 (15) 26-52 21-52 weeks 33-35 (Johnson, 1997)
Paclitaxel-cisplatin 219 (7) 42 (Range 31-52) 43-48 weeks 37-41 (Bunn, 1997)
Paclitaxel-carboplatin 518 (16) 39 (Range 25-62) 35-54.2 weeks 32-54 (Bunn, 1997)
Docetaxel-cisplatin 176 (4) 33-48 8-13 months 32-58 (Mattson et al, 1997)
Docetaxel-carboplatin 43 (3) 47 (36-75) No data No data (Belani et al, 1997;
Griesinger et al, 1997;
Schutte et al, 1997)
Irinotecan-cisplatin 135 (4) 42-54 44 weeks 33 (Masuda et al, 1998;
Ramanathan and Belani,
1997)
aNumber of trials in parentheses.
Table 3 Randomized trials involving new agents in non-small-cell lung cancer
Number Response Median survival 1-year P-value References
rate (%) survival (%)
Vinorelbine-cisplatin 182 30 40 weeks 35 (Le Chevalier et al, 1996)
Vindesine-cisplatin 179 19 32 weeks 27 0.04
Vinorelbine 188 14 31 weeks 30 0.01
Vinorelbine-cisplatin 214 25 7 months 33 (Wozniak et al, 1996)
Cisplatin 218 10 6 months 12 0.001
Gemcitabine 27 19.2 37 weeks - (Perng et al, 1997)
Cisplatin-etoposide 26 20.8 48 weeks - NS
Gemcitabine-cisplatin 69 40.5 8.7 months 30 (Lopez-Cabrerizo et al, 1997)
Cisplatin-etoposide 66 22.6 7.2 months 24 NS
Paclitaxel (250 mg m-2)-cisplatin 200 27.7 9.8 months 38.5 (Bonomi et al,1997)
Paclitaxel (135 mg m-2)-cisplatin 200 25.3
Cisplatin-etoposide 200 12.4 7.7 months 31.6 0.048
Paclitaxel (175 mg m-2)-cisplatin - 44 9.4 months - NS Giaccone et al, 1997)
Teniposide-cisplatin - 30 9.7 months
included both quality of life and pharmacoeconomic analyses. The
response rate was higher with the new combination (40.5% vs
22.6%); the median of duration of response was prolonged by 6
weeks; but the overall survival, quality of life and overall costs
were the same (Lopez-Cabrerizo et al, 1997).
These randomized trials can be interpreted in a number of ways.
All of these new regimens have higher response rates than our
standard treatments and therefore the implication is that, if cyto-
reduction before surgery can result in cure, then greater cyto-
reduction will result in further cure. However, the first part of the
hypothesis has yet to be proved conclusively, despite the encour-
aging results of two small randomized neoadjuvant studies (Rosell
et al, 1994; Roth et al, 1994). The results of larger studies are
keenly awaited before this approach can become standard.
Furthermore, care must be taken when introducing these new
agents with concomitant radiotherapy, as demonstrated in this
month's journal (Yokoyama et al, 1998).
In the palliative setting, these new combinations may offer
improved response rates and perhaps a modest prolongation of
progression-free survival. Thus, palliative treatment needs to be
assessed comparing data on rate and duration of symptom
improvement, quality of life and economic analysis. The effect on
overall survival is likely to be small, and none of these current
trials have been powered to show small survival benefits (5%
improvement over current treatments would require about 1000
patients in each trial). These issues will be debated fiercely from
British Journal of Cancer (1998) 78(2), 159-162 0 Cancer Research Campaign 1998Where to go with new expensive treatments in NSCLC 161
either side of the purchaser/provider standpoint before any new
regimens will be accepted for either trials or treatments.
From the UK point of view, we want to know whether these
treatments are better than our standard regimens. To carry out
these trials, we will have to recruit about 1000 patients to improve
on our current regimens (MVP and MIC). Currently, the market
for these new agents is small in the UK compared with the market
world-wide. It is therefore unlikely that the major pharmaceutical
companies will fund these initiatives unless there is a suggestion
that, if the new treatments prove better, they will become widely
used and available. Currently, we are not able to fund these trials
from drug budgets. It would appear that the whole system needs
major overhauling with dissection of each part of the pathway
leading to the introduction ofnew drugs.
Why are these new drugs so expensive? The reason is multifac-
torial. Firstly, these drugs appear to be expensive because, in the
past 15 years, there have been few new drugs in oncology and
therefore there has been no expansion in drug expenditure.
Currently, only 1% ofthe current drug budget in the NHS has been
spent on cytotoxic drugs. To catch up with this shortfall would take
a major influx of cash. In addition, we have now found situations
in which more patients require treatment with our old drugs; for
example, patients with colon cancer now require adjuvant treat-
ment with 5-fluorouracil (5-FU) and folinic acid (IMPACT, 1995),
and patients with node-negative breast cancer now require adju-
vant treatment with CMF (Fisher et al, 1997). However, the root of
the problem is that new technology is expensive and drug develop-
ment costs are now major. To develop one of the new taxoids has
taken in the region of £260 million over a 10-year period, with
investment purely by a pharmaceutical company. This leaves only
about 5 years oflicence remaining before the drug goes offpatent,
in other words 5 years to recoup the costs, make a profit and fund
further development. Profits have to be made quickly as the fear is
that when a drug comes off patent, competitor compounds will be
introduced and the prices will fall. However, this has not always
happened. For example, carboplatin is still one of our most expen-
sive drugs, despite the introduction of a generic competitor. The
same can be said for the price of anthracyclines, which, if
anything, have increased over recent years.
These issues can be confounded by human factors, such as the
influences ofdoctors and patients. Patients in the terminal phase of
their disease have sometimes unreal expectations as to what can be
achieved, often stimulated by media exaggeration of the facts.
However, if these expensive new agent combinations result in
genuine improvements in both palliation in the advanced setting
and cure, in the neoadjuvant orthe adjuvant setting, then long-term
solutions must be found. Furthermore, the potential for litigation
may loom if our cheap current therapies are shown to be substan-
dard. These are difficult problems to resolve and will require inno-
vative approaches to come up with a long-term solution. These
solutions must set in place systems that will be robust enough to
cope with the next 20 years.
The one thing that we have to offer in this country is good
quality research, which produces data that are reputable and that
are taken up widely and internationally. This is perhaps one of the
things that we should exploit. We propose that the whole system of
introducing new drugs should be re-examined and a system
evolved in which the development of new drugs becomes an NHS
research and development priority, with the handling of phase I,
II and III trials carried out at an NHS level, with no cost to the
pharmaceutical companies. This would immediately at least halve
the cost ofdrug development and therefore have a follow-on effect
on the price that new drugs are placed at in the market. A system of
loyalty could be evolved that would take the nervousness out of
developers and take away the fear of competitors. This would
guarantee loyalty over a period of 10-15 years with one product.
In return for all this, the NHS should be guaranteed a calculated
percentage of the pharmaceutical companies' world sales/profits
for this agent. This of course may threaten the major pharmaceu-
tical companies but should be seen in the light of pharmaceutical
companies and the NHS working hand-in-hand to our mutual
benefit. At the same time as implicated in the British Medical
Journal recently (Maynard and Bloor, 1997), the whole drug-
pricing process needs to be reviewed to make sure that these
agents are being introduced at a fair price. In addition, national
systems need to be put in place with a national formula, based on
consensus and fairness so that there is no unequal distribution of
therapies and thus no fear oflitigation. It is time for doctors to take
responsibility so that systems can be devised, because, if we do
not, there is only a limited number of solutions; these would take
the form ofincreased taxation, introduction ofa fee per item or the
development of insurance policies to cover serious illness or any
illness requiring high spending.
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